Andropause and Testosterone Therapy: What Truly Benefits Men
A man with a confirmed, symptomatic testosterone deficiency who begins properly managed therapy typically regains libido, improves mood and vitality, and the latest large-scale studies have dispelled long-standing concerns about cardiovascular safety (Lincoff et al., New England Journal of Medicine, 2023). Despite this, some men who meet the diagnostic criteria still do not receive the treatment recommended by guidelines (Endocrine Society, 2018). This is a genuine clinical issue, not a passing trend.
Andropause, also referred to as late-onset hypogonadism, is often described with excessive caution, as if the very idea of treatment were questionable. Yet, for a man with a confirmed deficiency, it is a treatable condition, and androgen therapy is the recognized first-line option (Endocrine Society guidelines, JCEM, 2018).
Andropause Is Not a Myth, It's a Treatable Deficiency
Late-onset hypogonadism, in Polish "późny hipogonadyzm," refers to a condition in aging men, often accompanied by obesity or chronic diseases, where low testosterone levels occur alongside symptoms. These typically include reduced libido, erectile dysfunction, fatigue, low mood, muscle mass loss, anemia, and decreased bone density.
The difference from the fear-driven narrative about therapy is clear. This is a recognizable syndrome with specific criteria and effective treatment, not an inevitable consequence of aging to simply accept. Diagnosis is made in men who exhibit symptoms and consistently low morning testosterone levels (Endocrine Society, patient material).
What Therapy Offers: Hard Evidence of Effectiveness
The most well-designed study series on testosterone in older men, known as the Testosterone Trials, included 790 men over the age of 65 with confirmed low testosterone levels (Snyder et al., New England Journal of Medicine, 2016). Raising hormone levels to the range typical for younger men was associated with significant improvements in sexual activity, desire, and erectile function, as well as better mood and reduced severity of depressive symptoms (Snyder et al., 2016).
The benefits extend beyond the sexual domain. Therapy corrected anemia and increased bone density and strength (Testosterone Trials review, 2020; Snyder et al., JAMA Internal Medicine, 2017). The position of the Endocrine Society states this clearly: for men with diagnosed, persistently low testosterone, treatment is safe and can be effective (Endocrine Society).
Safety: What the TRAVERSE Study Ultimately Revealed
For years, testosterone therapy was burdened by concerns about its impact on heart health, based on small and inconsistent studies. These concerns were addressed by TRAVERSE, the largest randomized, placebo-controlled trial involving over 5,000 men with hypogonadism and either cardiovascular disease or high cardiovascular risk (Lincoff et al., New England Journal of Medicine, 2023).
The results were reassuring. The therapy proved non-inferior to placebo in terms of major cardiovascular events and did not increase the incidence of prostate cancer (Lincoff et al., 2023). A European expert panel concluded that the TRAVERSE data provide robust evidence that testosterone treatment does not elevate the risk of major cardiovascular incidents, aligning with previous meta-analyses (European Expert Panel for Testosterone Research, Andrology, 2025).
Like any effective therapy, testosterone treatment is conducted with routine monitoring, such as blood counts, which is ensured through specialist care. Minor signals noted in the study are predictable and manageable within the framework of medical supervision (European Expert Panel, 2025). Supervision is not a barrier but a component that ensures the therapy remains safe.
Why Many Men Still Aren't Receiving Treatment
The issue is often the opposite of what the panic around misuse suggests. The Endocrine Society points out that some men with hypogonadism aren't getting the treatment they need (Endocrine Society, 2018). Several factors contribute to this: outdated concerns about heart risks, embarrassment about addressing the topic, and attributing symptoms solely to aging.
The alternative that discouraged men turn to is the worst possible option. Testosterone booster supplements and the hormone black market operate without diagnosis, dose control, or safety monitoring. This is the exact opposite of what properly managed therapy under a doctor's care provides.
The Role of Specialized Care
Properly managed testosterone therapy falls under the expertise of an endocrinologist, urologist, or men's health clinic. These professionals confirm the diagnosis, rule out reversible causes, rely on symptoms and repeated morning testosterone measurements, select the appropriate medication form, and monitor both treatment response and safety parameters (Endocrine Society guidelines, 2018).
This is the true value of professional care. Accurate qualification and supervision ensure that therapy is both effective and safe, distinguishing legitimate treatment from self-experimentation. The Endocrine Society emphasizes thorough diagnostics and a structured monitoring plan as hallmarks of good practice (Endocrine Society, 2018).
When to Seek Help
If you've been experiencing low libido, erectile dysfunction, decreased energy, and a drop in mood for a while, you don't have to endure it or dismiss it as a natural part of life. A sensible step is to visit a specialist and have your morning testosterone levels tested, with a follow-up test for confirmation (Snyder et al., 2016; Endocrine Society guidelines, 2018). If the tests confirm a deficiency, effective treatments are available, backed by large-scale, controlled studies that ensure their safety.
Andropause is not a marketing myth or a reason to give up. For men with a genuine testosterone deficiency, it is a treatable condition, and the path to improvement lies in professional diagnosis and therapy—not in supplements purchased online.
Worth Exploring Further
For readers who want to dive a level deeper, a great reference point is the academic monograph by Nieschlag E., Behre H.M., Nieschlag S., Testosterone. Action, Deficiency, Substitution, Cambridge University Press, current edition. This is a go-to resource for clinicians, covering the physiology, diagnostics, and androgen therapy with a comprehensive source apparatus.
Related articles on Affector worth checking out:
How to interpret testosterone results, reference values, and common interpretation errors: Link to the article
Sources
Lincoff A.M., Bhasin S., et al., Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE), New England Journal of Medicine, 2023, DOI 10.1056/NEJMoa2215025.
Snyder P.J., et al., Effects of Testosterone Treatment in Older Men (Testosterone Trials), New England Journal of Medicine, 2016.
Testosterone Replacement in Men with Age-Related Low Testosterone, What Did We Learn From The Testosterone Trials, review, 2020.
Snyder P.J., et al., Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men, JAMA Internal Medicine, 2017.
Bhasin S., et al., Testosterone Therapy in Men With Hypogonadism, An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2018.
Endocrine Society, Experts issue recommendations to improve testosterone prescribing practices, 2018.
Endocrine Society, Hypogonadism in Men, patient material.
Huhtaniemi I., Late-onset hypogonadism, current concepts and controversies of pathogenesis, diagnosis and treatment, Asian Journal of Andrology, 2014.
Zitzmann M., et al., Cardiovascular safety of testosterone therapy, insights from the TRAVERSE trial and beyond, Andrology, 2025, DOI 10.1111/andr.70062.